Loading
AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.
AZD0120 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 3 trials sponsored by AstraZeneca and Alexion Pharmaceuticals, Inc., in multiple myeloma. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
1.AZD0120 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD0120" OR ABSTRACT:"AZD0120") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD0120, not a curated reading list.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares Multiple myeloma and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.